Menu

Experience

Natasha Leskovsek

    • Neurocrine Partners With Takeda to Address Psychiatric Disorders 


    • Orca Bio Raises $192 Million Series D to Transform Allogenic Cell Therapy 


    • Avidity Biosciences - $289 Million IPO 


    • Vaxcyte - $288 Milion IPO 


    • Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech 


    • Forty Seven Agrees to Sell to Gilead for $4.9 Billion  


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • argenx – $557 Million Follow-On Offering 


    • Synthorx to Sell to Sanofi for $2.5 Billion 


    • Avidity Biosciences – $100 Million Series C 


    • Innate Pharma - $79 Million IPO 


    • Vir Biotechnology - $143 Million IPO 


    • Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million 


    • Crown Bioscience Enters Merger Agreement With JSR Corporation 


    • Sucampo Sells to Mallinckrodt for $1.2 Billion 


    • Cell Design Labs Sells to Gilead 


    • ERYTECH – $144 Million IPO 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Zealand Pharma – $89 Million IPO 


    • Aridis – $26 Million IPO 


    • Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out 


    • SELLAS Life Sciences Group to Merge with Galena Biopharma 


    • ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion 


    • Medivation Agrees to Sell to Pfizer for $14 Billion 


    • Advaxis – $30 Million Registered Direct Offering 


    • Recro Pharma – $15 Million Follow-On  


    • Gemphire Therapeutics – $30 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Selecta Biosciences – $74 Million IPO 


    • Jazz Pharmaceuticals Acquires Celator for $1.5 Billion 


    • Oncobiologics – $40 Million IPO and Private Placement 


    • Inotek Pharmaceuticals – $50 Million Follow-On 


    • Syndax – $58 Million IPO 


    • AveXis – $95 Million IPO 


    • WAVE Life Sciences - $102 Million IPO 


    • Voyager Therapeutics - $80.5 Million IPO 


    • Cardioxyl Pharmaceuticals sale to Bristol-Myers Squibb 


    • Strongbridge Biopharma IPO 


    • Aclaris Therapeutics IPO 


    • Bristol Meyers Enters Agreement with Five Prime 


    • Medivation Expanding Oncology Franchise with Acquisition of Talazoparib from BioMarin 


    • NantKwest IPO - $238 Million IPO 


    • ProNAi Therapeutics - $158 Million IPO 


    • Chiasma Completes $117 Million IPO 


    • Celyad Completes IPO 


    • NantKwest – $238 Million IPO 


    • Catabasis Completes $69 Million IPO 


    • ProNAi – $158 Million IPO 


    • Axovant Completes $362 Million IPO 


    • HTG Completes its Initial Public Offering 


    • Jawbone Acquisition of Body Media 


    • Aduro Completes $137 Million IPO 


    • KemPharm Completes its IPO 


    • Cidara Completes Initial Public Offering  


    • Auspex Pharma $3.5 billion sale to Teva Pharma 


    • Auspex Pharma Acquired by Teva for $3.5 Billion 


    • Horizon Pharma Acquires Hyperion Therapeutics for $1.1 Billion 


    • Invitae Completes $117 Million Initial Public Offering  


    • Ascendis Pharma closes $124 million IPO 


    • Bellicum Pharmaceuticals $160 million IPO 


    • Nexvet Biopharma Closes Initial Public Offering 


    • TRACON Pharmaceuticals Completes Initial Public Offering 


    • Cooley Advises Xencor on its Initial Public Offering 


    • NewLink Will License Ebola Vaccine to Merck 


    • Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes 


    • Ionis Pharmaceuticals Completes Rule 144A Offering $500 Million of Convertible Senior Notes 


    • Xenon Pharmaceuticals Completes Initial Public Offering 


    • Atara – $63 Million IPO and Follow-On Offerings 


    • DBV Technologies Completes Concurrent Public Offerings 


    • Vascular Biogenics Prices IPO 


    • Sientra Completes $75 Million Initial Public Offering 


    • Demira Prices $125 Million IPO 


    • T2 Biosystems IPO 


    • NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research & Development 


    • Vitae Pharmaceuticals Completes Initial Public Offering  


    • Otonomy $100 Million IPO 


    • Immune Design $63 Million Initial Public Offering 


    • GlobeImmune Initial Public Offering 


    • Intersect ENT Initial Public Offering 


    • Minerva Neurosciences $32.7 Million IPO 


    • Kite Pharma $146 Million Initial Public Offering 


    • ProteinSimple $300 Million Sale to Techne Corporation 


    • Alder Biopharmaceuticals $80 Million Initial Public Offering 


    • Adamas Pharmaceuticals Initial Public Offering 


    • TriVascular Initial Public Offering 


    • Vital Therapies Initial Public Offering 


    • Cooley Advises Underwriters on Vital Therapies IPO 


    • Versartis $145 Million IPO 


    • Horizon Pharma $660 Million Acquisition of Vidara Therapeutics 


    • Amedica Initial Public Offering 


    • Eagle $50 Million Initial Public Offering 


    • Flexion $74 Million Initial Public Offering 


    • Auspex $96 Million Initial Public Offering 


    • Egalet Corporation IPO 


    • Genocea Biosciences IPO 


    • Eleven Biotherapeutics IPO 


    • Revance $110 Million Initial Public Offering 


    • Cooley Advised Flexion on Initial Public Offering 


    • Celladon Initial Public Offering 


    • Trevena $64 Million Initial Public Offering 


    • Cara Therapeutics $55 Million Initial Public Offering